Urdafalk, which contains the active ingredient ursodiol (ursodeoxycholic acid), is a prescription medication utilized to assist in the management of specific liver and gallbladder conditions. Its therapeutic function is to promote symptomatic relief associated with these specific conditions.

The medicine is indicated for the treatment of patients with primary biliary cholangitis (PBC), a chronic liver condition. It is also used in the management of radiolucent, noncalcified gallbladder stones in select patients who are not candidates for surgery. Additionally, Urdafalk may be used to help reduce the risk of gallstone formation in patients experiencing rapid weight loss, such as those who have undergone bariatric surgery. The overall purpose of treatment is to assist in symptom management within the context of these specific clinical scenarios.

“The drug is used to help modulate the composition of bile.”

---

Quick Fact: Relief for Cholestasis Symptoms

Who can and cannot use Urdafalk?

Urdafalk's eligibility is determined by strict regulatory criteria documented in official prescribing information.

Contraindications (Who Must Not Use)

Use of this medicine is contraindicated in several populations, primarily those with specific hepatobiliary conditions. These absolute prohibitions include patients with acute inflammation of the gallbladder or biliary tract, a complete obstruction of the bile duct, decompensated hepatic cirrhosis (advanced liver failure), or frequent biliary colic. It is also contraindicated for patients with radio-opaque calcified gallstones, as the medicine will not dissolve this type of stone.

Eligibility and Restrictions

Adults and the elderly are the approved population. Use in children is established only for hepatobiliary disorders associated with Cystic Fibrosis (CF-HBD). Safety and efficacy for other uses, such as gallstone dissolution, are not established in the pediatric population. The medicine should only be used during pregnancy if clearly needed. Women of childbearing potential receiving treatment for gallstone dissolution must use effective non-hormonal contraception during therapy. All patients with chronic liver disease must undergo mandatory and regular monitoring of liver function tests.

The officially documented interaction profile for Urdafalk (Ursodiol) is organized around three primary regulatory classifications. This information is derived from official government prescribing documents.

Interactions that Reduce Urdafalk Efficacy

Urdafalk's absorption and subsequent effectiveness can be significantly reduced by medicinal products that bind bile acids in the intestine. This includes bile acid sequestering agents (e.g., Cholestyramine, Colestipol) and aluminum-based antacids. To avoid this physical interference, these substances must be administered at least 2 hours before or 2 hours after Urdafalk.

---

Pharmacodynamic and Exposure Interactions

The therapeutic goal of Urdafalk can be pharmacodynamically counteracted by substances that increase hepatic cholesterol secretion, such as oestrogenic hormones and related compounds (including oral contraceptives), and lipid-lowering drugs like Clofibrate. Furthermore, Urdafalk may affect the exposure of co-administered drugs. Plasma concentrations of Ciclosporin can be increased, while the concentrations of Nitrendipine and the effect of Dapsone may be reduced due to the potential influence on the CYP3A4 enzyme system and transport proteins. For gallstone dissolution, the label specifically requires the use of non-hormonal contraception.

Modification of Bile Fluid Composition

Urdafalk (Ursodiol) acts by competitively displacing the naturally occurring, more hydrophobic bile salts, thereby restructuring the bile acid pool. This molecular replacement introduces a more hydrophilic component, which significantly reduces the bile's overall hydrophobicity index and lowers the saturation of cholesterol. This change in chemical property creates the physiological condition necessary for the shift of cholesterol microcrystals from a solid phase back into a micellar phase.

Cellular Mechanism and Secretion Dynamics

The active ingredient operates through direct membrane stabilization, physically incorporating into the hepatocyte and cholangiocyte membranes. This integration shields liver cells from detergent-like damage caused by hydrophobic bile salts and inhibits the activation of the intrinsic apoptotic cascade, resulting in the maintenance of cellular structure. Simultaneously, Urdafalk functions as a choleretic agent by promoting the function and insertion of key apical transport proteins, such as BSEP and MRP2. This mechanism increases the volume and flow rate of bile, enhancing secretion dynamics and facilitating the transport of biliary substances out of the hepatic system.

How Urdafalk is Used: Administration Principles

Urdafalk (ursodiol) is administered exclusively via the oral route, utilizing specific weight-based or fixed-dose regimens. The administration pattern is designed to ensure consistent drug presence in the body.

---

Standard Dosing and Frequency

The following table describes the typical dosing principles for specific conditions:

Indication	Dosing Principle	Frequency Pattern
Primary Biliary Cholangitis (PBC)	13–15 mg/kg/day	Typically administered in 2–4 divided doses per day; may transition to once daily in the evening for long-term use.
Gallstone Dissolution	8–10 mg/kg/day	Divided into 2–3 doses per day.
Gallstone Prevention	Fixed daily dose (e.g., 600 mg/day)	Administered twice daily (BID).

For PBC, treatment is typically long-term or chronic. In contrast, gallstone dissolution is a time-bound course often requiring up to two years, and may be discontinued if no dissolution is observed after 12 months.

---

Administration Context and Procedural Rules

Standard guidelines provide specific instructions on the timing and handling of the medicine to ensure proper absorption:

• Timing with Meals: Urdafalk is generally recommended to be taken with meals to facilitate absorption. The total daily dose is typically divided and spread throughout the day.
• Handling of Tablets: Scored tablets may be broken in half to achieve the prescribed amount; however, the segments must be swallowed whole with water and must not be chewed.
• Procedural Constraint: To prevent interference with absorption, Urdafalk must be administered at least two hours before or after the intake of aluminum-containing antacids or bile acid sequestrants (such as cholestyramine). If a dose is missed, it should not be doubled; the regular schedule should be continued.

Research Evidence / Overview of Studies for Urdafalk

Urdafalk (ursodiol) research has primarily focused on the research related to chronic liver conditions and certain gallbladder issues. The clinical evaluation is built upon established study types, including randomized controlled trials (RCTs), systematic reviews, and analyses of patient data collected over many years.

---

Evidence for Use in Primary Biliary Cholangitis (PBC)

The most extensive research base for ursodiol focuses on the research related to patients with Primary Biliary Cholangitis (PBC). Studies monitored hard outcomes, such as transplant-free survival, and tracked changes in liver function biochemical markers. Findings describe patterns observed where the compound was associated with differences in long-term outcomes. However, studies report that a portion of individuals may not achieve a defined adequate response, which was associated with patterns of disease progression.

---

Evidence for Gallstone Endpoints

Urdafalk was studied for its potential role in gallstone endpoints for specific types of gallstones without surgery. Research was conducted using prospective clinical trials on stones categorized as radiolucent and non-calcified. Studies monitored the complete endpoint of the gallstone and the rate of recurrence in the years following successful dissolution. The evidence remains limited to specific populations, and the studies describe a high rate of recurrence observed in follow-up.

---

Evidence for Gallstone Incidence During Rapid Weight Loss

Urdafalk was evaluated in studies researching the incidence of new gallstone formation in individuals undergoing rapid weight loss, primarily after bariatric surgery. Research was built upon multiple RCTs and meta-analyses. Findings reported a lower incidence rate of new gallstone formation in the observed groups compared to those who received a placebo.

---

Long-Term Studies and Durability of Follow-up

For PBC, studies monitored responses over defined time intervals, tracking patient outcomes for extended periods, sometimes exceeding a decade. For gallstone endpoints, long-term follow-up focuses mainly on monitoring the rate of recurrence. For gallstone prevention, long-term effects are not fully established, as most RCTs monitored outcomes only up to one year.

---

Evidence in Specific Patient Groups and Remaining Uncertainty

Research primarily explored the compound in adult populations. Data for children and adolescents remain insufficient. The documented rate of inadequate change in biochemical markers for PBC highlights an area where researchers are exploring variability in individual patterns. Overall, the certainty remains low regarding the evaluation and optimal use in specific, underrepresented patient subgroups.

How to Store and Dispose of Urdafalk

The storage and disposal of Ursofalk (ursodiol) must adhere to official regulatory requirements to ensure product stability and safety. The hard capsules must be stored at a temperature not exceeding 25°C (77°F). The unopened granules for oral suspension may be stored below 30 C.

Stability and Handling

For the reconstituted oral suspension, the maximum storage temperature is 25 C, and it must be discarded after 4 months.

Disposal and Safety

All forms of the medicine must be kept out of the sight and reach of children. Unused or expired Ursofalk must not be disposed of in wastewater or household waste; instead, it must be disposed of according to local requirements for pharmaceutical waste.